Galecto (GLTO) Competitors $10.99 -0.69 (-5.91%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$10.13 -0.86 (-7.83%) As of 05:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLTO vs. TMQ, ANL, NRXP, ICCC, QNTM, OTLK, ELYM, CELU, GNTA, and ALGSShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Trilogy Metals (TMQ), Adlai Nortye (ANL), NRx Pharmaceuticals (NRXP), ImmuCell (ICCC), Quantum Biopharma (QNTM), Oncobiologics (OTLK), Eliem Therapeutics (ELYM), Celularity (CELU), Genenta Science (GNTA), and Aligos Therapeutics (ALGS). Galecto vs. Its Competitors Trilogy Metals Adlai Nortye NRx Pharmaceuticals ImmuCell Quantum Biopharma Oncobiologics Eliem Therapeutics Celularity Genenta Science Aligos Therapeutics Galecto (NASDAQ:GLTO) and Trilogy Metals (NYSEAMERICAN:TMQ) are related small-cap companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Which has more risk & volatility, GLTO or TMQ? Galecto has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Trilogy Metals has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Do analysts prefer GLTO or TMQ? Trilogy Metals has a consensus target price of $7.75, indicating a potential upside of 9.15%. Given Trilogy Metals' stronger consensus rating and higher probable upside, analysts clearly believe Trilogy Metals is more favorable than Galecto.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galecto 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Trilogy Metals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders have more ownership in GLTO or TMQ? 14.2% of Galecto shares are held by institutional investors. Comparatively, 16.8% of Trilogy Metals shares are held by institutional investors. 10.8% of Galecto shares are held by insiders. Comparatively, 15.2% of Trilogy Metals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer GLTO or TMQ? In the previous week, Trilogy Metals had 35 more articles in the media than Galecto. MarketBeat recorded 37 mentions for Trilogy Metals and 2 mentions for Galecto. Trilogy Metals' average media sentiment score of 0.41 beat Galecto's score of 0.18 indicating that Trilogy Metals is being referred to more favorably in the news media. Company Overall Sentiment Galecto Neutral Trilogy Metals Neutral Which has preferable valuation and earnings, GLTO or TMQ? Trilogy Metals is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectoN/AN/A-$21.44M-$13.13-0.84Trilogy MetalsN/AN/A-$8.59M-$0.05-142.00 Is GLTO or TMQ more profitable? Trilogy Metals' return on equity of -7.02% beat Galecto's return on equity.Company Net Margins Return on Equity Return on Assets GalectoN/A -115.70% -95.42% Trilogy Metals N/A -7.02%-6.98% SummaryTrilogy Metals beats Galecto on 11 of the 13 factors compared between the two stocks. Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.46M$3.41B$6.08B$10.55BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-0.8423.0784.6127.19Price / SalesN/A486.15597.35132.96Price / CashN/A46.9737.8662.13Price / Book1.0010.5012.456.65Net Income-$21.44M-$52.47M$3.32B$276.79M7 Day Performance-13.19%2.90%2.27%1.75%1 Month Performance285.61%15.36%9.64%5.15%1 Year Performance63.30%14.29%74.87%36.96% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto0.6792 of 5 stars$10.99-5.9%N/A+63.8%$15.46MN/A-0.8440Analyst ForecastShort Interest ↑TMQTrilogy Metals2.3665 of 5 stars$9.60+46.3%$7.75-19.2%+1,252.4%$1.59BN/A-193.465Short Interest ↓Gap UpHigh Trading VolumeANLAdlai Nortye1.2626 of 5 stars$1.68+4.8%$9.00+437.3%-16.9%$60.89M$5M0.00127Short Interest ↑NRXPNRx Pharmaceuticals3.166 of 5 stars$3.07-1.6%$34.50+1,023.8%+147.2%$60.84MN/A-1.372Analyst ForecastICCCImmuCell1.0654 of 5 stars$6.67+1.3%N/A+75.6%$60.32M$26.49M35.0870Gap UpQNTMQuantum Biopharma0.5115 of 5 stars$15.69+3.3%N/A+179.6%$59.92MN/A-1.12N/AOTLKOncobiologics2.714 of 5 stars$1.35+2.7%$7.00+420.4%-74.2%$59.75MN/A-2.3620ELYMEliem TherapeuticsN/A$2.00+11.1%N/A-64.3%$59.50MN/A-3.779CELUCelularity2.6806 of 5 stars$2.22+8.6%$6.00+170.9%-23.4%$59.12M$54.22M-0.70220Short Interest ↓Gap DownHigh Trading VolumeGNTAGenenta Science0.99 of 5 stars$3.15-9.2%N/A-43.2%$57.61MN/A0.007ALGSAligos Therapeutics3.8939 of 5 stars$9.36-1.2%$50.00+434.4%+42.4%$57.47M$3.94M-0.4790News Coverage Related Companies and Tools Related Companies Trilogy Metals Competitors Adlai Nortye Competitors NRx Pharmaceuticals Competitors ImmuCell Competitors Quantum Biopharma Competitors Oncobiologics Competitors Eliem Therapeutics Competitors Celularity Competitors Genenta Science Competitors Aligos Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLTO) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
